Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Improving the Prognosis and Treatment of Osteoarthritis with Quantitative MRI

By BiotechDaily International staff writers
Posted on 20 May 2013
A new project’s goal is to assess multiple imaging and biochemical biomarkers to find more comprehensive ways to evaluate both the progression of the disease and the effectiveness of new treatments.

The Biomarkers Consortium (Bethesda, MD, USA; Mount Laurel, NJ, USA), a public-private partnership managed by the Foundation for the US National Institutes of Health (FNIH; Bethesda, MD, USA),reported that substantial progress is being made in the FNIH Osteoarthritis (OA) Biomarkers Project, which seeks to improve clinical outcomes for nearly 30 million people in the United States living with OA of the knee and for those at risk for developing the disease.

Preliminary findings from quantitative magnetic resonance imaging (qMRI) of femur, fibula, and patella periarticular bone area, three-dimensional (3D) bone shape and joint space width show significant differences between patients with progressive OA and nonprogressing control subjects at early study time points (baseline to 24 months) and are predictive of clinical OA progression in the knee over 48 months. This is the first report of changes of defined biomarkers of bone shape being predictive of OA progression and highlights their superior ability to measure early and subtle changes in OA progression compared to traditional radiographic measures. These findings were presented at the Osteoarthritis Research Society International (OARSI) World Congress, held in Philadelphia (PA, USA), April 2013.

The project, now into its second year, continues on an aggressive stride to investigate further quantitative and semiquantitative image evaluations of bone and cartilage changes in the knee joint by mid-2013. Furthermore, testing on 12 biochemical markers using serum and urine from the study cohort has begun to assess joint tissue metabolism. These biochemical markers can also provide a direct measure of drug effect and mechanism of action to help better refine customized treatments for OA.

The OA Biomarkers Project is being led by two scientists from OARSI, Dr. David Hunter at the University of Sydney and Dr. Virginia Byers Kraus at Duke University (Durham, NC, USA). The project is run under the direction of the Biomarkers Consortium, a public-private biomedical research partnership managed by the FNIH and combines expertise from the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and pharmaceutical and biotech companies, academia, and disease-focused nonprofit organizations.

Related Links:
Biomarkers Consortium
Foundation for the US National Institutes of Health


comments powered by Disqus

Channels

Genomics/Proteomics

view channel

New Program Encourages Wide Distribution of Genomic Data

A new data sharing program allows genomics researchers and practitioners to analyze, visualize, and share raw sequence data for individual patients or across populations straight from a local browser. The sequencing revolution is providing the raw data required to identify the genetic variants underlying rare diseases... Read more

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.